UK-based medical technology company Quanta, which develops compact but advanced haemodialysis systems - under the brand 'SC+' - for use in the home and in clinics, has secured $48 million in Series C funding.
The financing round was led by a Swiss private family office in combination with btov Partners and co-led by Wellington Partners and Seroba Life Sciences, the company said, along with participation from other existing investors.
The company says proceeds from the round will be used to fund the UK commercial launch of SC+, and a 510(k) submission to the FDA later this year so it can make its debut in the United States.
Christian Schütz, Partner at btov Partners, said: "There are approximately 3.5 million dialysis patients globally and there has been very little innovation over the years. We are confident that SC+ will provide a much-needed solution to help health systems deliver better value for money whilst at the same time improving patients’ lives."